Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Beebe

Showing results (141-150 of 147) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 147 results.
Arthritis Research & Therapy|June 6, 2024
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritisStanley Cohen, Jean S Beebe, Vishala Chindalore, et al.
Advances in Therapy|April 30, 2010
PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseasesHerbert A Runnels, Gregory L Weber, Jing Min, et al.
Genome Biology|October 21, 2018
Discovering in vivo cytokine-eQTL interactions from a lupus clinical trialEmma E Davenport, Tiffany Amariuta, Maria Gutierrez-Arcelus, et al.
Ebiomedicine|May 4, 2019
Interleukin-8 as a therapeutic target for chronic low back pain: Upregulation in human cerebrospinal fluid and pre-clinical validation with chronic reparixin in the SPARC-null mouse modelEmerson Krock, Magali Millecamps, Kathleen M Anderson, et al.
Cancer Research|November 13, 2003
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapyJean S Beebe, Jitesh P Jani, Elisabeth Knauth, et al.
Lancet (London, England)|January 11, 2025
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trialDavid Fiorentino, Aaron R Mangold, Victoria P Werth, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2013
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumorsJoel T Arcari, Jean S Beebe, Martin A Berliner, et al.
Pageof 15

Showing results (141-150 of 147) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 147 results.
Arthritis Research & Therapy|June 6, 2024
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritisStanley Cohen, Jean S Beebe, Vishala Chindalore, et al.
Advances in Therapy|April 30, 2010
PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseasesHerbert A Runnels, Gregory L Weber, Jing Min, et al.
Genome Biology|October 21, 2018
Discovering in vivo cytokine-eQTL interactions from a lupus clinical trialEmma E Davenport, Tiffany Amariuta, Maria Gutierrez-Arcelus, et al.
Ebiomedicine|May 4, 2019
Interleukin-8 as a therapeutic target for chronic low back pain: Upregulation in human cerebrospinal fluid and pre-clinical validation with chronic reparixin in the SPARC-null mouse modelEmerson Krock, Magali Millecamps, Kathleen M Anderson, et al.
Cancer Research|November 13, 2003
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapyJean S Beebe, Jitesh P Jani, Elisabeth Knauth, et al.
Lancet (London, England)|January 11, 2025
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trialDavid Fiorentino, Aaron R Mangold, Victoria P Werth, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2013
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumorsJoel T Arcari, Jean S Beebe, Martin A Berliner, et al.
Pageof 15